Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajpe.2025.101457 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Internalizing symptoms are indirectly associated with simultaneous alcohol and cannabis use through specific motives for simultaneous use: A longitudinal study of young adults.
Alcohol Clin Exp Res (Hoboken)
September 2025
Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Background: This study examined motivational pathways between internalizing symptoms (i.e., depression, anxiety, stress) and simultaneous alcohol and cannabis use among young adults.
View Article and Find Full Text PDFIntegration of Patient Reported Outcomes Data among People with HIV in Washington, DC: A sub-cohort of the DC Cohort Longitudinal Study.
J Public Health (Berl)
July 2025
Department of Epidemiology, George Washington University (GWU), Washington, DC, USA.
Aim: Patient reported outcomes (PROs) can help to evaluate gaps and areas for improvement along the HIV care continuum. We sought to describe the methodology and processes of a PROs study within the DC Cohort study population, describe the PROs results to date, report on lessons learned, and describe future directions of the research.
Subject And Methods: Each study site recruited participants from the DC Cohort, a longitudinal study on people with HIV, to complete the electronic PROs baseline and annual follow-up surveys, which consisted of previously validated measures of social determinants of health, mental health, substance use, medication adherence, and other related measures.
Weekly changes in ventilation response for photon and proton lung cancer patients during radiotherapy.
medRxiv
August 2025
Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Purpose: Conformal dose distributions in proton radiotherapy promise to reduce normal tissue toxicity such as radiation-induced pneumonitis, but this has not been fully realized in clinical trials. To further investigate dose and toxicity, we employ voxel-based normal tissue evaluation techniques such as ventilation maps throughout treatment. We hypothesize that ventilation change after 1 week of treatment (WK1) predicts for ventilation change at the end of treatment (EOT).
View Article and Find Full Text PDFAmygdala-liver signalling orchestrates glycaemic responses to stress.
Nature
September 2025
Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Behavioural adaptations to environmental threats are crucial for survival and necessitate rapid deployment of energy reserves. The amygdala coordinates behavioural adaptations to threats, but little is known about its involvement in underpinning metabolic adaptations. Here we show that acute stress activates medial amygdala (MeA) neurons that innervate the ventromedial hypothalamus (MeA neurons), which precipitates hyperglycaemia and hypophagia.
View Article and Find Full Text PDFVericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
August 2025
Université de Lorraine, Inserm CIC 1433, CHRU, Nancy, France.
Background: Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to assess the effect of vericiguat in patients with HFrEF without recent heart failure worsening.
Methods: In this double-blind, placebo-controlled, phase 3 trial, conducted at 482 sites across 36 countries, patients aged 18 years or older with HFrEF (left ventricular ejection fraction of ≤40%) without heart failure hospitalisation within 6 months or outpatient intravenous diuretic use within 3 months before randomisation were randomly assigned (1:1) using an intervention randomisation system with interactive response technology to oral vericiguat (target 10 mg dose) or matching placebo.